Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Relationship between transforming growth factor β1 and progression of hypertensive renal disease

Journal of Human Hypertension volume 16, pages 641–645 (2002)Cite this article

Abstract

In this study the role of circulating transforming growth factor β1 (TGFβ1) on progression of renal hypertensive disease has been investigated. Fifty consecutive outpatients with essential hypertension were enrolled and divided into three groups, according to their urinary albumin excretion (UAE). Group A comprised 10 hypertensives with UAE ⩽20 mg/24 h (normoalbuminuric group); Group B included 21 hypertensives with UAE > 20 < 300 mg/24 h (microalbuminuric group); Group C encompassed 19 hypertensives with UAE ⩾ 300 mg/24 h (proteinuric group). In all patients UAE by immunonephelometric assay, circulating TGFβ1 by a solid phase specific sandwich ELISA technique, BUN and creatinine by routine laboratory methods were determined. In addition, left ventricular telediastolic internal diameter, interventricular septum diastolic (IVSTd), posterior wall thickness, total and normalised to height2.7 left ventricular mass, relative wall thickness and left ventricular ejection fraction by M-B Mode echocardiography were calculated. Our results indicated that TGFβ1 levels were significantly (P < 0.05) higher in Group B and C than Group A and in Group C than Group B. In addition IVSTd values were significantly (P < 0.05) higher in both Group B and C than Group A. An evident, but not significant, higher prevalence of subjects with left ventricular hypertrophy were observed in Group C as compared with other groups. In all hypertensive subjects TGFβ1 correlated directly with UAE (P < 0.0001) but not with BMI, LVM/h2.7 and mean blood pressure. Our data indicated that TGFβ1 might be considered a useful marker to evaluate the severity and progression of hypertensive renal disease. Additional long-term clinical data are needed to evaluate whether inhibition of TGFβ1 system may prolong the time to the ESRD in hypertensive patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kannel WB . Blood pressure as cardiovascular risk factor JAMA 1996 275: 1571–1576

    Article  CAS  Google Scholar 

  2. Petty HM Jr et al. Early predictors of 15-year end-stage-renal disease in hypertensivepatients Hypertension 1995 25: 587–594

    Article  Google Scholar 

  3. Lindeman RD, Tobin JD, Shock NW . Association between blood pressure and the rate of decline in renal function with age Kidney Int 1984 26: 861–868

    Article  CAS  PubMed  Google Scholar 

  4. Weinstock W, Keane WF . Proteinuria and cardiovascular disease Am J Kidney Dis 2001 38 (Suppl 1): S8–S13

    Google Scholar 

  5. Roberts AM, Sporn MB . Transforming growth factor β Adv Cancer Res 1988 51: 107–145

    Article  CAS  PubMed  Google Scholar 

  6. Roberts AM, Mc Cune BK, Sporn MB . TGF-β: regulation of extracellular matrix Kidney Int 1992 41: 557–559

    Article  CAS  PubMed  Google Scholar 

  7. Border WA, Nobel NA . Transforming growth factor-β in tissue fibrosis N Engl J Med 1994 331: 1286–1292

    Article  CAS  PubMed  Google Scholar 

  8. Bottinger EP, Letterio JJ, Roberts AB . Biology of TGF-β in knockout and transgenic mouse models Kidney Int 1997 51: 1255–1360

    Article  Google Scholar 

  9. Laviades C, Varo N, Diez J . Transforming growth factor β in hypertensives with cardiorenal damage Hypertension 2000 36: 517–522

    Article  CAS  PubMed  Google Scholar 

  10. Li B et al. TGFβ1 DNA polymorphisms, protein levels, and blood pressure Hypertension 1999 33: 271–275

    Article  CAS  PubMed  Google Scholar 

  11. Suthanthiran M et al. Transforming growth factor β1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage Proc Natl Acad Sci USA 2000 97: 3479–3484

    CAS  PubMed  Google Scholar 

  12. Derhaschnig U et al. Increase levels of transforming growth factor β1 in essential hypertension Am J Hypertens 2001 14 (Suppl 1): A169–A170

    Article  Google Scholar 

  13. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 1997 157: 2413–2446

  14. Khanna A, Li B, Stenzel KH, Suthanthiran M . Regulation of new DNA synthesis in mammalian cells by ciclosporine: demonstration of a transforming growth β factor dependent mechanism of inhibition of cell growth Transplantation 1994 57: 577–582

    Article  CAS  PubMed  Google Scholar 

  15. De Simone G et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk J Am Coll Cardiol 1995 25: 1056–1062

    Article  CAS  PubMed  Google Scholar 

  16. De Simone G et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight J Am Coll Cardiol 1992 20: 1251–1260

    Article  CAS  PubMed  Google Scholar 

  17. De Simone G et al. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults Hypertension 1994 23: 600–606

    Article  CAS  PubMed  Google Scholar 

  18. Urbina E et al. Effects of body size, ponderosity and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study Circulation 1995 25: 1056–1062

    Google Scholar 

  19. Wyatt HI et al. Cross sectional echocardiography III. Analysis of mathematic models for quantifying volume of symmetric and asymmetric left ventricular Am Heart J 1980 100: 821–828

    Article  CAS  PubMed  Google Scholar 

  20. Corrao S, Scaglione R, Arnone S, Licata G . Left ventricular diastolic filling alterations in subjects with mitral valve prolapse: a doppler echocardiography study Eur Heart J 1993 14: 369–372

    Article  CAS  PubMed  Google Scholar 

  21. Watchell K et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study Hypertension 2000 35: 6–12

    Article  Google Scholar 

  22. Ketteler M, Noble NA, Border WA . Increased expression of transforming growth factor beta in renal disease Curr Opin Nephrol Hyperters 1994 3: 446–452

    Article  CAS  Google Scholar 

  23. Ziyadeh FN et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice Proc Natl Acad Sci USA 2000 97: 8015–8020

    Article  CAS  PubMed  Google Scholar 

  24. Dahly AJ et al. Chronic anti TGFβ Ab therapy reduces proteinuria and renal injury in hypertensive rats J Am Soc Nephrol 2000 11: 332A

    Google Scholar 

  25. Border WA, Nobel NA . Interactions of transforming growth factor-β and angiotensin II in renal fibrosis Hypertension 1998 3: 181–188

    Article  Google Scholar 

  26. Remuzzi G, Bertani T . Pathophysiology of progressive nephropathies N Engl J Med 1998 339: 1448–1456

    Article  CAS  PubMed  Google Scholar 

  27. Sharma K et al. Captopril-induced reduction of serum levels of transforming growth factor-β correlates with long term renoprotection in insulin-dependent diabeticpatients Am J Kidney Dis 1999 34: 818–823

    Article  CAS  PubMed  Google Scholar 

  28. Gyu-Tae Shin et al. ACE inhibitors attenuate expression of renal transforming growth factor-β1 in humans Am J Kidney Dis 2000 36: 894–902

    Article  Google Scholar 

  29. Pinto YM et al. Reduction in left ventricular messanger RNA for transforming growth factor β1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR (mRen2) 27 rat Hypertension 2000 36: 747–754

    Article  CAS  PubMed  Google Scholar 

  30. Noble NA, Border WA . Angiotensin II in renal fibrosis: should TGFβ rather than blood pressure be the therapeutic target? Semin Nephrol 1997 17: 445–466

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chair of Medical Therapy, University of Palermo, Italy

    R Scaglione

  2. Department of Internal Medicine, University of Palermo, Italy

    C Argano, G Parrinello, D Colomba, T Di Chiara, A Ferrante, V Di Garbo, G Avellone & G Licata

Authors
  1. R Scaglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Argano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Parrinello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Colomba
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Di Chiara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Ferrante
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V Di Garbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Avellone
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Licata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Scaglione.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scaglione, R., Argano, C., Parrinello, G. et al. Relationship between transforming growth factor β1 and progression of hypertensive renal disease. J Hum Hypertens 16, 641–645 (2002). https://doi.org/10.1038/sj.jhh.1001465

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001465

Keywords

This article is cited by

Search

Advanced search

Quick links